| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Journal Article |
Institute of Hematology and Medical Oncology L. e A. Seragnoli, University of Bologna, Italy. plzinzo@med.unibo.it
BACKGROUND AND OBJECTIVES: Although remission of hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) appears to be long lasting, few reports currently provide results from follow-up exceeding 5 years. DESIGN AND METHODS: We reviewed our HCL patients treated with front-line 2-CdA (by 2-hour infusion) either for 5 consecutive days at 0.14 mg/kg/day (daily subset, n=21) or once a week at 0.14 mg/kg for 5 cycles (weekly subset, n=16). RESULTS: Of the 37 eligible patients, 30 (81%) achieved complete response (CR) and 7 (19%) partial response (PR) (overall response rate, 100%); identical response rates were recorded in the daily and weekly subsets. After a median follow-up of 122 months (range, 54-156), the overall relapse rate was 27% (8/30): 24% (4/17) had relapsed in the subset treated daily whereas 30% (4/13) had done so in the subset treated weekly (p=ns). The projected 13-year overall and the relapse-free survivals are 96% and 52%, respectively. In terms of hematologic toxicity, the weekly 2-CdA schedule was associated with significantly fewer cases of grade 3-4 neutropenia. INTERPRETATION AND CONCLUSIONS: In HCL patients, a single dose of 2-CdA induces a long-term CR. Over 90% of patients are alive 13 years later and over 50% of patients appear to be clinically cured by this treatment. The weekly schedule seems to be a safer option for neutropenic HCL patients, while apparently providing equivalent results in terms of response rates and long-term outcome.
This article has been cited by other articles:
|
|
 |
|
  T. Robak, K. Jamroziak, J. Gora-Tybor, J. Z. Blonski, M. Kasznicki, J. Dwilewicz-Trojaczek, E. Wiater, A. Zdunczyk, J. Dybowicz, A. Dmoszynska, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial Blood, May 1, 2007; 109(9): 3672 - 3675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. O. Wanko and C. de Castro Hairy Cell Leukemia: An Elusive but Treatable Disease Oncologist, July 1, 2006; 11(7): 780 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ravandi and S. O'Brien Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., December 1, 2005; 80(12): 1660 - 1674. [Abstract] [PDF]
|
|
|
|
|
|
P. Chadha, A. W. Rademaker, P. Mendiratta, B. Kim, D. M. Evanchuk, D. Hakimian, L. C. Peterson, and M. S. Tallman Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience Blood, July 1, 2005; 106(1): 241 - 246. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
